Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders. The company is headquartered in Plymouth Meeting, Pennsylvania. Show more

630 WEST GERMANTOWN PIKE, PLYMOUTH MEETING, PA, UNITED STATES, 19462, Plymouth Meeting, PA, 19462, USA

https://www.harmonybiosciences.com

BIOTECHNOLOGY

HEALTHCARE

Start AI Chat

Market Cap

2.032B

52 Wk Range

$25.52 - $40.87

Previous Close

$35.28

Open

$35.38

Volume

1,448,503

Day Range

$34.07 - $35.52

Enterprise Value

1.57B

Cash

647M

Avg Qtr Burn

N/A

Insider Ownership

12.14%

Institutional Own.

91.81%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
WAKIX® (pitolisant) Details Narcolepsy	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
WAKIX® (pitolisant) Details Excessive daytime sleepiness, Genetic disorder, Cataplexy, Narcolepsy, Prader-Willi syndrome	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
WAKIX® (pitolisant) Details EDS in Idiopathic Hypersomnia	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
WAKIX/Pitolisant HD (H3 Antagonist) Details Narcolepsy	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
EPX-100 (clemizole hydrochloride) Details Dravet syndrome	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
EPX-100 (clemizole hydrochloride) Details Lennox-Gastaut Syndrome (LGS)	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
WAKIX® (pitolisant) Details Rare genetic disease, Genetic disorder, Prader-Willi syndrome, Excessive daytime sleepiness	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
WAKIX® (pitolisant) Details Muscle weakness, Muscle degeneration, Myotonic Dystrophy Type 1	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BP1.15205 Details Narcolepsy, idiopathic hypersomnia and other central disorders of hypersomnolence	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TPM-1116 [orexin-2 receptor agonist] Details Narcolepsy, Sleep-wake disorder	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lorcaserin Hydrochloride (EPX-200) (5HT2 Agonist) Details Developmental And Epileptic Encephalopathies	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zygel (ZYN002 CBD Gel) Details Rare genetic disease, Genetic disorder, Deletion Syndrome , 22q11.2 deletion syndrome	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zygel (ZYN002 CBD Gel) Details Rare genetic disease, Genetic disorder, Fragile X syndrome	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.